Quezia Jones
Comment: Rife with WP:AIATTR, far too much for it to be coincidental. Athanelar (talk) 22:39, 12 September 2026 (UTC)
- Comment: If this is resubmitted, for the next reviewer please see the discussion at WP:AFCHD#17:46, 12 September 2026 review of submission by CedarAtlasNotes as the creator made some arguments that might be relevant. S0091 (talk) 20:32, 12 September 2026 (UTC)
- Comment: WP:Too soon Jishara (please ping upon response) (talk) 16:25, 12 September 2026 (UTC)
| Quezia Jones | |
|---|---|
| Born | |
| 🏫 Education | State University of Ceará; Federal University of Ceará |
| 💼 Occupation | |
| 🌐 Website | www |
Quezia Jones (publishes academically as Quezia Damaris Jones Severino Vasconcelos) is a Brazilian nutrition scientist and researcher whose work has included nutritional supplementation, gastrointestinal biology, neuroinflammation, the gut–brain axis, and autism spectrum disorder (ASD).[1][2] She studied at the State University of Ceará (UECE) and the Federal University of Ceará (UFC), and completed a doctorate in Physiological Sciences at UECE in 2026.[3][4]
Education and career
Jones studied Nutrition at UECE and later completed a professional master's degree in Clinical Pharmacology at UFC.[1][3] Her master's dissertation examined whey-protein supplementation, gut dysbiosis and behavioral outcomes in a valproic-acid animal model associated with autism.[3]
She subsequently entered the doctoral program in Physiological Sciences at UECE. During her doctorate, she undertook a doctoral-sandwich research period at Lancaster University in the United Kingdom; UOL identified her as carrying out research there in 2023.[1] Her doctoral research at UECE examined the neuroprotective effects of Croton lechleri latex in preclinical models associated with autism following valproic-acid exposure.[5] UECE announced the defense of her doctoral thesis in March 2026.[4]
Her published research has included affiliations with the Drug Research and Development Center at UFC and research groups at UECE.[6][7]
Research
Jones's earlier research concerned nutritional supplementation and gastrointestinal biology. She was first author of a 2021 systematic review in Applied Physiology, Nutrition, and Metabolism examining reported adverse effects associated with whey-protein supplementation.[6] The review was subsequently the subject of a published discussion by nutrition researcher Caio Eduardo Gonçalves Reis, who disputed aspects of its conclusions; Vasconcelos and her co-authors published a reply in the same journal.[8][9]
Jones also co-authored a series of reviews concerning fructans and fructooligosaccharides (FOS). A 2020 review in Archives de Pédiatrie examined nutrient absorption in children and adolescents,[10] a 2021 systematic review in Clinical Nutrition ESPEN assessed mineral and trace-element absorption,[11] and a 2022 review in Nutrition Reviews examined FOS in relation to inflammation, oxidative stress, immunomodulation and the gut immune response.[12]
Jones was first author of a 2024 experimental study in Future Microbiology examining whey-protein supplementation and gut microbiota in Wistar rats exposed to valproic acid.[13] Her later work has focused more directly on experimental and clinical evidence related to autism. She was first author of a 2025 systematic review of valproate exposure as an in-vitro model for studying morpho-molecular features associated with ASD.[14]
Jones has also participated in research on cannabinoid-based interventions for autism. A 2025 report in Diário do Nordeste identified her among collaborators on a UECE-led project examining cannabidiol for children and adolescents with ASD.[15] UECE likewise listed Jones among the LANIT/GENIT collaborators.[7] Speaking to the Ceará news outlet GC Mais, Jones said that the available clinical literature reported benefits in some behavioral domains while remaining inconclusive because studies varied in cannabis preparation, dosage and treatment duration, and because long-term pediatric data were lacking.[16]
In 2026, Jones was first author of a systematic review in Progress in Neuro-Psychopharmacology and Biological Psychiatry assessing the safety and effectiveness of cannabinoid-based interventions for behavioral outcomes in children and adolescents with ASD.[2][17] The review concluded that evidence for behavioral benefit remained uncertain because of methodological limitations.[17] She was also a co-author of a 2026 Psychopharmacology systematic review examining isolated cannabidiol in animal models of autism.[18]
References
- ↑ 1.0 1.1 1.2 Almeida, Cristina (12 September 2023). "O que acontece no seu corpo quando você toma whey regularmente". VivaBem (in português). UOL. Retrieved 12 September 2026.
- ↑ 2.0 2.1 Vasconcelos, Quezia Damaris Jones Severino; de Freitas, Renê Felipe; Freitas, Madna Costa; de Andrade, Isadora Porto; Brandão, Carla Barbosa; Nascimento, Cidianna Emanuelly; Neves, Kelly Rose; Magalhães, Paulo Sávio; Barbosa Filho, Valter; Oliveira, Giovanna Lima; de Moura, Matheus Alisson Melo; Aragão, Gislei Frota (2026). "Cannabinoid-based interventions for behavioral outcomes in children and adolescents with autism spectrum disorder: A systematic review of safety and effectiveness". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 146. doi:10.1016/j.pnpbp.2026.111697. PMID 41974303 Check
|pmid=value (help). Unknown parameter|article-number=ignored (help) - ↑ 3.0 3.1 3.2 "Uso de whey protein para tratar disbiose de ratos wistar com sintomas de autismo induzidos por ácido valproico". Repositório Institucional da Universidade Federal do Ceará (in português). 2022. Retrieved 12 September 2026.
- ↑ 4.0 4.1 "Defesa de tese da aluna Quezia Damaris Jones Severino Vasconcelos". Programa de Pós-Graduação em Ciências Fisiológicas (in português). Universidade Estadual do Ceará. 31 March 2026. Retrieved 12 September 2026.
- ↑ "Exame de Qualificação de Doutorado da QUEZIA DAMARIS JONES SEVERINO VASCONCELOS". Programa de Pós-Graduação em Ciências Fisiológicas (in português). Universidade Estadual do Ceará. 6 December 2024. Retrieved 12 September 2026.
- ↑ 6.0 6.1 Vasconcelos, Quezia Damaris Jones Severino; Bachur, Tatiana Paschoalette Rodrigues; Aragão, Gislei Frota (2021). "Whey protein supplementation and its potentially adverse effects on health: a systematic review". Applied Physiology, Nutrition, and Metabolism. 46 (1): 27–33. doi:10.1139/apnm-2020-0370. hdl:1807/103906. PMID 32702243 Check
|pmid=value (help). - ↑ 7.0 7.1 "Canabidiol no TEA: o que revela a pesquisa da Uece". Universidade Estadual do Ceará (in português). 14 July 2025. Retrieved 12 September 2026.
- ↑ Reis, Caio Eduardo Gonçalves (2021). "Discussion of "Whey protein supplementation and its potentially adverse effects on health: a systematic review" – Unsubstantiated claims of adverse effects of whey protein supplementation on human kidney and liver function". Applied Physiology, Nutrition, and Metabolism. 46 (1): 90–91. doi:10.1139/apnm-2020-0674. PMID 33399522 Check
|pmid=value (help). - ↑ Vasconcelos, Quezia Damaris Jones Severino; Bachur, Tatiana Paschoalette Rodrigues; Aragão, Gislei Frota (2021). "Reply to "Discussion of 'Whey protein supplementation and its potentially adverse effects on health: a systematic review' – Unsubstantiated claims of adverse effects of whey protein supplementation on human kidney and liver function"". Applied Physiology, Nutrition, and Metabolism. 46 (1): 92–93. doi:10.1139/apnm-2020-0731. hdl:1807/104059. PMID 33399523 Check
|pmid=value (help). - ↑ Costa, Graciana; Vasconcelos, Quezia; Abreu, Giselle; Albuquerque, Annanda; Vilarejo, Janaina; Aragão, Gislei (2020). "Changes in nutrient absorption in children and adolescents caused by fructans, especially fructooligosaccharides and inulin". Archives de Pédiatrie. 27 (3): 166–169. doi:10.1016/j.arcped.2020.01.004. PMID 32127241 Check
|pmid=value (help). - ↑ Costa, Graciana T.; Vasconcelos, Quezia D. J. S.; Abreu, Giselle C.; Albuquerque, Annanda O.; Vilar, Janaina L.; Aragão, Gislei F. (2021). "Systematic review of the ingestion of fructooligosaccharides on the absorption of minerals and trace elements versus control groups". Clinical Nutrition ESPEN. 41: 68–76. doi:10.1016/j.clnesp.2020.11.007. PMID 33487309 Check
|pmid=value (help). - ↑ Costa, Graciana T.; Vasconcelos, Quezia D. J. S.; Aragão, Gislei F. (2022). "Fructooligosaccharides on inflammation, immunomodulation, oxidative stress, and gut immune response: a systematic review". Nutrition Reviews. 80 (4): 709–722. doi:10.1093/nutrit/nuab115. PMID 34966938 Check
|pmid=value (help). - ↑ Vasconcelos, Quezia Damaris Jones Severino; Frederico, Marisa Jadna Silva; Alves, Renata de Sousa; Bandeira, Tereza de Jesus Pinheiro Gomes; Moraes, Maria Elisabete Amaral de; Aragão, Gislei Frota (2024). "Effects of whey protein supplementation on gut microbiota of Wistar rats with valproic acid-induced autism symptoms". Future Microbiology. 19 (3): 213–226. doi:10.2217/fmb-2023-0051. PMID 37934065 Check
|pmid=value (help). - ↑ Vasconcelos, Quezia Damaris Jones Severino; Serafini, Michele Aramburu; Carletti, Jaqueline Vieira; Aragão, Gislei Frota; Gottfried, Carmem; Bambini-Junior, Victorio (2025). "Valproate Exposure as an In vitro Model for Studying Morpho-Molecular Features of ASD: A Systematic Review". CNS & Neurological Disorders - Drug Targets. 24 (10): 766–778. doi:10.2174/0118715273374315250417094713. PMID 40296624 Check
|pmid=value (help). - ↑ Nascimento, Clarice (12 August 2025). "Canabidiol tem efeitos positivos limitados no tratamento de TEA, revela pesquisa da Uece". Diário do Nordeste (in português). Retrieved 12 September 2026.
- ↑ "Pesquisa da Uece aponta potencial do canabidiol no tratamento de crianças autistas". GC Mais (in português). 16 July 2025. Retrieved 12 September 2026.
- ↑ 17.0 17.1 Vasconcelos QDJS; De Freitas, R. F.; Freitas, M. C.; De Andrade, I. P.; Brandão, C. B.; Nascimento, C. E.; Neves, K. R.; Magalhães, P. S.; Filho, V. B.; Oliveira, G. L.; de Moura MAM; Aragão, G. F. (2 April 2026). "Cannabinoid-based interventions for behavioral outcomes in children and adolescents with autism spectrum disorder: A systematic review of safety and effectiveness". Progress in Neuro-Psychopharmacology & Biological Psychiatry. Elsevier. 146. doi:10.1016/j.pnpbp.2026.111697. PMID 41974303 Check
|pmid=value (help). Retrieved 12 September 2026. Unknown parameter|article-number=ignored (help) - ↑ Milhome Vasconcelos, Iara Késsila; Pitombeira, Maria Helena da Silva; Fontenele, David Ribeiro; Vasconcelos, Quezia Damaris Jones Severino; Aragão, Gislei Frota (2026). "Behavioral pharmacology of isolated cannabidiol in animal models of autism spectrum disorder: a systematic review". Psychopharmacology. doi:10.1007/s00213-026-07149-x. PMID 42616101 Check
|pmid=value (help).
External links
This article "Quezia Jones" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Quezia Jones. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
